MAGENTA THERAPEUTICSCS INC
MAGENTA THERAPEUTICSCS INC
Share · US55910K1088 · MGTA · A2JPD6 (XNMS)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 0,00 % -93,00 %

Company Profile for MAGENTA THERAPEUTICSCS INC Share

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Invested Funds

The following funds have invested in: MAGENTA THERAPEUTICSCS INC invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
12,52
Percentage (%)
0,03 %

Company Data

Name MAGENTA THERAPEUTICSCS INC
Company Magenta Therapeutics, Inc.
Symbol MGTA
Website https://www.magentatx.com
Primary Exchange XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN A2JPD6
ISIN US55910K1088
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Stephen F. Mahoney J.D., MBA
Market Capitalization 42 Mio
Country United States of America
Currency USD
Employees 0,1 T
Address 100 Technology Square, 02139 Cambridge
IPO Date 2018-06-21

Ticker Symbols

Name Symbol
NASDAQ MGTA

More Shares

Investors who MAGENTA THERAPEUTICSCS INC hold also have the following shares in their portfolio:
ACTIVISION BLIZZARD INC
ACTIVISION BLIZZARD INC Share
ADTRAN HOLDINGS INC
ADTRAN HOLDINGS INC Share
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
BROADCO INC
BROADCO INC Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
CONDUENT INC
CONDUENT INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
DEKA MTN SERIE 7654
DEKA MTN SERIE 7654 Bond
DWS NOMUR.JAP.GROWTH LCHP
DWS NOMUR.JAP.GROWTH LCHP Fund
INTEL CORP
INTEL CORP Share
MICROSOFT CORP
MICROSOFT CORP Share
MORGAN STANLEY $ VAR RTE NTS 09/05/22
MORGAN STANLEY $ VAR RTE NTS 09/05/22 Bond
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025